Dr. Raheja has expanded psychiatric care through telepsychiatry, bringing services to rural Wisconsin at Thedacare Regional ...

People with schizophrenia experience impaired contrast perception, affecting their ability to differentiate light intensity and recognize shapes and textures.

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

BioXcel Therapeutics (BTAI) provided an update on the progress of its late-stage clinical programs for lead neuroscience asset BXCL501, as well ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

As its shares pop in Friday's session, pharmaceutical giant AbbVie Inc. (ABBV) posted a fourth quarter revenue beat and ...

NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company focused on artificial ...

Co-founders Dr Greg Stewart, Associate Professor Jess Nithianantharajah and Professor Chris LangmeadFounded in 2022, Phrenix Therapeutics is the first ...

Phrenix Therapeutics, a cutting-edge biotech company focused on next-generation medicines for psychiatric and neurological disorders, has secured significant seed investment from specialist biotech ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.